10-K: Waystar Reports Strong 2025 Growth, Net Income Surge, Driven by AI & Strategic Acquisitions

Sentiment:

Annual Report 17 February 2026 6:49 AM

Waystar Holding Corp. achieved significant financial growth in 2025, reporting a net income of $112.1 million and a 16.5% revenue increase, bolstered by its AI-powered platform and the strategic acquisition of Iodine Software.

Capital raiseThe company completed an Initial Public Offering (IPO) in June 2024, issuing 45,000,000 shares and raising $914.3 million, with an additional $102.8 million from the underwriters' overallotment option in July 2024.Institutional Investors conducted three secondary public offerings in February, May, and September 2025, selling a total of 55,375,000 shares of common stock. Waystar did not receive proceeds but paid $4.6 million in expenses.The company may need to engage in equity or debt financings or collaborative arrangements to secure additional funds for future growth, product development, infrastructure enhancement, and potential acquisitions.The First Lien Credit Facility was increased by $250.0 million on October 1, 2025, as part of the Iodine acquisition financing.The Revolving Credit Facility's maximum borrowing capacity was increased from $400.0 million to $500.0 million on October 1, 2025.The Receivables Facility credit availability was increased from $80.0 million to $100.0 million on February 13, 2026 (post-period event).

Better than expectedNet income of $112.1 million in 2025 significantly exceeded the net loss of $19.1 million in 2024.Revenue growth of 16.5% to $1,099.3 million demonstrates strong top-line performance.Adjusted EBITDA increased by 20.5% to $462.1 million, indicating improved operational profitability.Net Revenue Retention Rate of 112.0% is a positive indicator of customer satisfaction and growth within the existing client base.Operating cash flow increased substantially from $169.8 million in 2024 to $309.7 million in 2025.

Summary

Waystar Holding Corp. reported a net income of $112.1 million for the year ended December 31, 2025, a significant improvement from a net loss of $19.1 million in 2024.
Total revenue increased by 16.5% to $1,099.3 million in 2025, up from $943.5 million in 2024.
Adjusted EBITDA grew by 20.5% to $462.1 million in 2025, compared to $383.5 million in 2024.
The Net Revenue Retention Rate was 112.0% for 2025, indicating strong client expansion and retention.
The company acquired Iodine Software Holdings, Inc. on October 1, 2025, for $1.26 billion, comprising $638.9 million in cash and 16,639,920 shares of common stock.
A cybersecurity incident involving a competitor in February 2024 led to Waystar gaining over 30,000 new providers, contributing approximately $11 million in additional revenue in 2025 and $34 million in 2024.
Waystar's platform processed over 7.5 billion healthcare payment transactions in 2025, representing over $2.4 trillion in gross claims volume.
The company's total addressable market (TAM) was estimated at $20 billion in 2025, with a projected CAGR of 5% to almost $25 billion by 2030.
Outstanding indebtedness as of December 31, 2025, was approximately $1.5 billion, consisting of $1.4 billion under the First Lien Credit Facility and $80 million under the Receivables Facility.
Cash and cash equivalents decreased from $182.1 million in 2024 to $61.4 million in 2025, primarily due to the cash component of the Iodine acquisition.
Operating cash flow increased significantly to $309.7 million in 2025 from $169.8 million in 2024.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by a significant return to net profitability, robust revenue growth, and strategic acquisitions. The company's strong market position and AI innovation underpin a positive outlook, despite increased debt and cash outflow for acquisitions.

Positives

Significant turnaround from a net loss of $19.1 million in 2024 to a net income of $112.1 million in 2025.
Strong revenue growth of 16.5% year-over-year, reaching $1,099.3 million.
Adjusted EBITDA increased by 20.5% to $462.1 million, demonstrating improved operational profitability.
High Net Revenue Retention Rate of 112.0% indicates strong customer loyalty and successful upselling/cross-selling.
Growth in high-value clients, with 1,391 clients generating over $100,000 in revenue in 2025, up from 1,203 in 2024.
Strategic acquisition of Iodine Software enhances AI leadership and expands clinical intelligence capabilities.
Benefited from a competitor's cybersecurity incident, acquiring over 30,000 new providers and generating $11 million in additional revenue in 2025.
Robust AI-powered platform (Waystar AltitudeAI) drives automation, accuracy, and efficiency in healthcare payments.
Strong market position, serving over 30,000 clients, including 16 of 20 U.S. News Best Hospitals.
Positive cash flow from operating activities increased significantly to $309.7 million in 2025 from $169.8 million in 2024.
Successful IPO in June 2024, raising over $1 billion and enabling substantial debt reduction.
Strong company culture and employee engagement, with 85% of team members recommending Waystar as a workplace.

Negatives

Cash and cash equivalents decreased significantly from $182.1 million in 2024 to $61.4 million in 2025, largely due to the cash component of the Iodine acquisition.
Substantial debt of approximately $1.5 billion, which could limit financial flexibility and expose the company to interest rate fluctuations.
Increased operating expenses across cost of revenue, sales and marketing, general and administrative, and research and development.
Significant increase in cash used in investing activities ($680.9 million in 2025 vs. $27.3 million in 2024) due to the Iodine acquisition.
The company had net losses in 2022 and 2023, indicating that sustained profitability is a recent achievement.
The issuance of preferred stock in the future could adversely affect common stockholders by restricting dividends, diluting voting power, or subordinating liquidation rights.
Anti-takeover provisions in corporate documents could deter beneficial acquisition attempts for stockholders.

Risks

Operating in a highly competitive and fragmented industry with rapidly evolving technology and regulatory requirements.
Ability to retain existing clients and attract new ones, as contracts typically have 2-3 year terms with one-year automatic renewals and termination clauses.
Challenges in successfully executing business strategies, including identifying and integrating acquisitions.
Dependence on strategic relationships with EHR and PM providers; loss or changes in these relationships could be costly.
Revenue reliance on client growth and overall healthcare transaction volumes, which are subject to external factors like economic conditions and governmental policies.
Long and variable selling cycles (weeks to 18+ months) and implementation cycles dependent on client timing and resources.
Dependence on senior management and key employees, and the ability to attract and retain skilled talent, especially in AI and software.
Inaccuracy of estimates and assumptions used to determine the total addressable market.
Inability to develop and market new solutions or enhance existing ones to keep pace with technological and regulatory changes.
Reliance on interoperability, connectivity, and integration with clients' and vendors' networks and infrastructures.
Dependence on the performance and reliability of internet, mobile, and other infrastructure not under Waystar's control.
Adverse effects if unable to obtain, process, use, disclose, or distribute highly regulated data in compliance with laws.
Reliance on certain third-party vendors and providers for critical services, including clearinghouse systems and payment processing.
Potential liability from errors or malfunctions in products and solutions, leading to client claims or reputational harm.
Risks of embezzlement, identity theft, or other illegal behavior by employees or vendors, and failure of employees or vendors to observe quality/ESG standards.
Compliance with NACHA rules and card network requirements, including potential fee increases or termination of registration.
Impact of payer and provider conduct outside of Waystar's control, such as direct links between providers and payers reducing transaction volumes.
Cyber-attacks, security breaches, or other incidents impacting information technology systems and data, including personal health information (PHI).
Complex and evolving laws and regulations regarding privacy, data protection, and cybersecurity (e.g., HIPAA, CCPA, CPRA, My Health My Data Act, FTC Act, HBNR).
Challenges in protecting and enforcing intellectual property rights, especially concerning AI technologies.
Dependence on the ability to use or license data and integrate third-party technologies.
Risks associated with the development, deployment, and use of AI, including data quality, performance degradation, client reluctance, and evolving regulatory environments.
Potential adverse effects from the use of open source software, including litigation or intellectual property disclosure requirements.
Legal proceedings initiated by third parties alleging intellectual property infringement.
Claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.
Conducting business in a heavily regulated industry, including fraud and abuse laws (AKS, FCA, Stark Law) and corporate practice of medicine prohibitions.
Uncertain and evolving healthcare regulatory and political framework, including changes in reimbursement models (value-based care, No Surprises Act).
Potential for legal, regulatory, and other proceedings resulting in adverse outcomes, fines, or operational changes.
Contractual requirements to comply with Bank Secrecy Act and Anti-Money Laundering (BSA/AML) laws.
Regulation of marketing activities by laws like CAN-SPAM Act and TCPA.
Need to comply fully with website accessibility standards.
Changes in tax rates, new tax legislation (e.g., TCJA's R&D capitalization), or exposure to additional tax liabilities.
Limitations on the ability to use net operating losses (NOLs) to offset future taxable income.
Potential for losses due to asset impairment charges, particularly goodwill and intangible assets (92% of total assets).
Substantial debt ($1.5 billion) and restrictive covenants in credit agreements.
Exposure to interest rate fluctuations due to variable-rate debt.
Unavailability of additional capital on acceptable terms for future growth.
Impact of general macroeconomic conditions, including inflation, supply chain issues, and recession risk.
History of net losses and the ability to achieve or maintain profitability.
Significant percentage of common stock held by certain investors whose interests may differ from other stockholders.
Increased costs and regulatory requirements as a public company, diverting management time.
Risk of failure to design, implement, and maintain effective internal controls.
Volatility in the market price of common stock.
Future issuances of common stock may dilute existing ownership.
No current plans to pay cash dividends, limiting return on investment for stockholders.
Future sales by existing stockholders could cause stock price decline.
Reliance on securities analysts' coverage; downgrades or cessation could impact stock price.
Anti-takeover provisions in organizational documents could delay or prevent a change of control.
Board's authority to issue preferred stock without stockholder approval, potentially diluting common stock value.
Exclusive forum provisions in the certificate of incorporation could limit stockholders' ability to choose a favorable judicial forum.

Future Outlook

Waystar expects to continue growing its market share by expanding relationships with existing clients, acquiring new clients, deepening strategic channel partnerships, and innovating new AI-powered solutions to achieve an autonomous revenue cycle. The total addressable market is projected to grow by a 5% CAGR to almost $25 billion by 2030. The company plans to make significant investments in business growth, product development, and infrastructure, potentially through additional debt or equity financings.

Management Comments

Our mission is to simplify healthcare payments through our modern cloud-based software, enabling our healthcare clients to prioritize patient care and optimize their financial performance.
Our software helps providers get paid faster, accurately, and more efficiently, while ensuring patients receive a modern, transparent, and consumer-friendly financial experience.
Our business model aligns with our clients' growth; as they serve more patients, claims and transactional volumes increase, driving corresponding growth in our business.
We believe our modern, cloud-based platform combined with our subject matter expertise is extremely difficult to replicate and provides us with a meaningful competitive advantage.
Our values-driven and award-winning leadership team brings together deep experience in the software and healthcare industries and strong relationships with our clients and key stakeholders.
We believe our team has the strategic vision, leadership qualities, technological expertise, and operational capabilities to continue to successfully drive our growth.
Our innovation strategy is centered on accelerating the path to the autonomous revenue cycle, leverage agentic AI to move beyond task-specific automation toward a system that can independently navigate complex payment workflows, leveraging clinical, financial and administrative data.
We are able to responsibly manage technical debt, allowing us to focus our investment on continuously innovating and advancing our platform for the benefit of our clients.
We believe that our existing unrestricted cash on hand, expected future cash flows from operations, and additional borrowings will provide sufficient resources to fund our operating requirements, as well as future capital expenditures, debt service requirements, and investments in future growth for at least the next 12 months.

Industry Context

StockSavvy.ai notes that Waystar operates in the highly complex and growing U.S. healthcare market, which accounted for 18.0% of GDP in 2024 and is projected to reach 20.3% by 2033. The industry faces significant administrative costs ($440 billion annually) and challenges with antiquated technology, manual processes, and increasing labor costs. Waystar's focus on AI-powered, cloud-based solutions positions it well to address these inefficiencies and capitalize on the accelerating consumer demand for digital healthcare tools. The company's ability to gain significant market share following a competitor's cybersecurity incident highlights the critical need for reliable and secure payment processing solutions in the sector.

Comparison to Industry Standards

Waystar's Net Revenue Retention Rate of 112.0% for 2025 is strong, indicating effective client retention and expansion, which is a key performance indicator for SaaS companies.
The company's 85% win rate against competitors from 2023-2025 in vendor-switching scenarios demonstrates a competitive advantage in product quality and client satisfaction.
Serving 16 of the top 20 U.S. News Best Hospitals indicates a strong presence among leading healthcare providers, suggesting enterprise-grade solution capabilities.
The company's 99.9% uptime for its platform is a competitive standard for mission-critical healthcare IT services, comparable to high-availability requirements in other regulated industries.
Waystar's early and deep integration of AI (50% of solutions leverage AI, Waystar AltitudeAI) positions it ahead of many traditional revenue cycle technology vendors who often rely on legacy systems.
The estimated total addressable market (TAM) of $20 billion in 2025, growing to $25 billion by 2030, suggests ample room for growth compared to its current market share of approximately 4% in the hospital segment and 8% in the ambulatory practice segment.
The company's PCI-DSS Level 1 Service Provider, HITRUST R2, and SSAE 18 SOC 2 Type II certifications demonstrate adherence to stringent industry security and compliance standards, which is crucial in the highly regulated healthcare data environment.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Structure	Board of directors is divided into three classes with staggered three-year terms until Institutional Investors collectively own less than 15% of voting power, after which directors will be elected for one-year terms.	June 10, 2024 (effective date of amended and restated certificate of incorporation)	Enhances continuity and stability, but may make it more difficult for stockholders to change board composition or effect a hostile change of control.
Director Nomination Rights	EQT, CPPIB, Bain, and Advent have rights to nominate directors based on their beneficial ownership percentages (e.g., EQT: two nominees for >=25% ownership, one for >=5%; CPPIB/Bain/Advent: one nominee for >=5% ownership).	June 10, 2024 (effective date of amended and restated certificate of incorporation)	Provides significant influence to major institutional investors over board composition and strategic direction.
Committee Appointments	As long as EQT, CPPIB, and Bain collectively own >=5% of common stock, their nominees will be appointed to specific committees (Audit, Compliance, & Risk; Talent & Compensation; Nominating and Corporate Governance).	June 10, 2024 (effective date of amended and restated certificate of incorporation)	Ensures significant investor representation and influence on key governance committees.
Preferred Stock Authorization	Board of directors is authorized to establish and issue one or more series of preferred stock (100,000,000 shares authorized) without further stockholder action, determining terms and rights.	June 10, 2024 (effective date of amended and restated certificate of incorporation)	Could impede or discourage acquisition attempts, restrict common stock dividends, dilute voting power, or subordinate liquidation rights of common stock.
Anti-Takeover Provisions	Includes provisions similar to DGCL Section 203 regarding business combinations with interested stockholders, advance notice requirements for nominations/proposals, limitations on special stockholder meetings and written consent, and supermajority voting requirements for certain amendments during a 'Protective Period'.	June 10, 2024 (effective date of amended and restated certificate of incorporation)	Intended to enhance continuity and stability, avoid costly takeover battles, and reduce vulnerability to hostile change of control, but may deter transactions beneficial to stockholders.
Director Removal	Directors may be removed with or without cause by majority vote, but during the 'Protective Period' (when Institutional Investors own <40% but before Triggering Annual Meeting), removal requires 66 2/3% vote and only for cause. EQT, CPPIB, or Bain have exclusive right to remove their nominees.	June 10, 2024 (effective date of amended and restated certificate of incorporation)	Protects board stability, especially during the 'Proteotive Period', and grants significant control to major investors over their nominees.
No Cumulative Voting	Amended and restated certificate of incorporation does not authorize cumulative voting.	June 10, 2024 (effective date of amended and restated certificate of incorporation)	Allows stockholders holding a majority of voting power to elect all directors, potentially limiting minority stockholder representation.
Exclusive Forum Provision	Designates the Court of Chancery of Delaware as the sole and exclusive forum for certain corporate litigation matters, and federal district courts for federal securities law claims.	June 10, 2024 (effective date of amended and restated certificate of incorporation)	May limit stockholders' ability to choose a favorable judicial forum, potentially discouraging certain lawsuits.
Conflicts of Interest Renunciation	Renounces any interest or expectancy in certain business opportunities presented to non-employee directors or Institutional Investors, allowing them to pursue such opportunities.	June 10, 2024 (effective date of amended and restated certificate of incorporation)	Allows non-employee directors and major investors to engage in competing business activities, potentially diverting opportunities from Waystar.
Limitations on Liability and Indemnification	Eliminates personal liability of directors and officers for monetary damages for breach of fiduciary duty (except for certain egregious acts) and provides for indemnification and expense advancement to the fullest extent authorized by DGCL.	June 10, 2024 (effective date of amended and restated certificate of incorporation)	May discourage stockholders from suing directors/officers for fiduciary duty breaches and reduces likelihood of derivative litigation.
Non-Employee Director Compensation Policy	Establishes cash and equity compensation for non-employee directors, including annual retainers ($50,000 for board service, additional for committee roles) and annual RSU awards ($200,000 value, vesting over one year or until next annual meeting).	August 5, 2025	Aims to align director interests with shareholders and remain competitive in attracting talent; subject to Plan limits.
Securities Trading Policy	Amended policy prohibits insider trading, short sales, hedging, speculative transactions, margin accounts, and pledges of company securities. Requires pre-clearance for 'Restricted Persons' and limits trading to 'Window Periods'.	August 5, 2025	Enhances compliance with securities laws and prevents insider trading, protecting company reputation and integrity. Imposes strict rules on trading for certain personnel.

Legal Proceedings

The company is subject to various claims and legal actions in the ordinary course of business, including employment-related matters. Currently, there are no material pending legal proceedings, and no claims are expected to have a material effect on the consolidated financial position, results of operations, or cash flows.

Related Party Transactions

As of December 31, 2025, $64.8 million of outstanding debt under the First Lien Credit Facility was held by Bain Affiliated Funds and CPPIB Credit Investments III Inc.
Interest expense paid to Affiliated Debtholders was $3.5 million in 2025, $4.5 million in 2024, and $7.6 million in 2023.
Canada Pension Plan Investment Board (CPPIB) has an ownership interest in Waystar and a significant interest in a landlord leasing office space to Waystar in Houston, Texas. Lease expenses were $0.2 million in 2024 and $0.3 million in 2023.
Bain Capital LP has an ownership interest in Waystar and significant interests in some clients from whom Waystar earned $2.5 million in 2025, $1.9 million in 2024, and $1.5 million in 2023.
Bain Capital LP also has significant interests in some vendors from whom Waystar expensed $2.8 million in 2025, $2.1 million in 2024, and $0.4 million in 2023 for software services.
Subsequent to the Iodine acquisition, Advent International, L.P. has an ownership interest in Waystar and significant interests in some clients from whom Waystar earned $0.7 million in 2025.
Advent also has a significant interest in one vendor from whom Waystar expensed $0.1 million for software services in 2025.

Stakeholder Impact

Shareholders: Positive financial results (net income, revenue, EBITDA growth) and strategic acquisitions could enhance shareholder value. However, future equity issuances could dilute ownership, and anti-takeover provisions may limit opportunities for premium acquisition offers. No current plans for cash dividends mean returns are primarily through stock appreciation.
Employees: Strong company culture, competitive benefits, 401(k), ESPP, paid family leave, and investment in training and development (including AI skills) indicate a positive environment. No collective bargaining agreements.
Customers (Healthcare Providers): Benefit from AI-powered software that simplifies payments, increases revenue, expedites payments, improves productivity, and provides financial visibility. High client satisfaction and retention rates suggest positive impact.
Suppliers/Vendors: Waystar relies on third-party vendors for critical services, and its relationships with them are important for business operations. Some vendors are related parties.
Creditors: Substantial debt ($1.5 billion) and restrictive covenants mean creditors have significant claims and influence. The company's improved profitability and cash flow from operations enhance its ability to service debt.
Regulatory Bodies: The company operates in a heavily regulated industry and is subject to extensive federal and state laws (HIPAA, fraud and abuse, data privacy, AI regulations). Compliance is a significant ongoing effort and risk.

Next Steps

Continue expanding relationships with existing clients through cross-selling and up-selling.
Grow the client base by targeting the estimated 7.5 million providers who can benefit from solutions.
Deepen and expand strategic channel partnerships.
Invest heavily in the Waystar platform to expand product breadth and depth, increase automation, and improve user experience.
Accelerate the path to an autonomous revenue cycle using agentic AI.
Selectively pursue strategic acquisitions that enhance the platform and accelerate growth.
Comply with post-closing matters related to the Receivables Facility and Purchase and Sale Agreement amendments by March 13, 2026, and April 13, 2026.
Matthew J. Hawkins' 10b5-1 trading plan is set to expire on August 19, 2026.

Key Dates

Date	Description
August 13, 2019	Waystar Holding Corp. originally incorporated in Delaware.
October 22, 2019	First Lien Credit Agreement and Second Lien Credit Agreement entered into.
September 23, 2020	Second Amendment to First Lien Credit Agreement.
March 24, 2021	Third Amendment to First Lien Credit Agreement.
August 12, 2021	Receivables Financing Agreement entered into.
August 24, 2021	Fourth Amendment to First Lien Credit Agreement.
November 30, 2022	Two interest rate swaps matured.
January 13, 2023	Entered into an interest rate swap.
June 1, 2023	Fifth Amendment to First Lien Credit Agreement.
June 23, 2023	Sixth Amendment to First Lien Credit Agreement.
August 3, 2023	Acquisition of HealthPay24 completed.
October 6, 2023	Seventh Amendment to First Lien Credit Agreement.
October 31, 2023	Acquired certain assets of Olive AI, Inc.'s Clearinghouse and Patient Access businesses; Amendment No. 1 to Receivables Financing Agreement.
December 31, 2023	Fiscal year end.
February 9, 2024	Eighth Amendment to First Lien Credit Agreement, extending maturity and refinancing outstanding balance; Second Lien Credit Facility fully paid down.
February 2024	Cybersecurity incident involving a competitor occurred, leading to Waystar gaining new providers.
May 15, 2024	Effected a 0.605-for-1 reverse stock split.
May 22, 2024	Retroactively amended reverse stock split ratio to 0.605-for-1.
June 6, 2024	Effective date of 2024 Equity Incentive Plan and 2024 Employee Stock Purchase Plan.
June 10, 2024	Amended and Restated Certificate of Incorporation became effective; Stockholders Agreement and Amended and Restated Registration Rights Agreement dated.
June 27, 2024	Ninth Amendment to First Lien Credit Agreement, repricing outstanding balance.
July 5, 2024	Underwriters exercised overallotment option for IPO shares.
September 6, 2024	Used $10.0 million drawn on the Receivables Facility to pay down First Lien Credit Facility.
December 30, 2024	Tenth Amendment to First Lien Credit Agreement, repricing outstanding balance and increasing Revolving Credit Facility capacity.
December 31, 2024	Fiscal year end.
February 24, 2025	First Secondary Offering by Institutional Investors.
April 1, 2025	Entered into an interest rate swap.
April 9, 2025	Entered into an interest rate swap.
May 15, 2025	Second Secondary Offering by Institutional Investors.
July 23, 2025	Entered into Agreement and Plan of Merger to acquire Iodine.
August 5, 2025	Effective date of Non-Employee Director Compensation Policy.
August 12, 2025	Eleventh Amendment to First Lien Credit Agreement, repricing outstanding balance.
September 10, 2025	Third Secondary Offering by Institutional Investors.
September 24, 2025	Non-Employee Director Compensation Policy adopted.
October 1, 2025	Acquisition of Iodine completed; Twelfth Amendment to First Lien Credit Agreement, increasing facility and revolving credit capacity, and decreasing interest rate; Entered into an interest rate cap.
December 31, 2025	Fiscal year end.
January 31, 2026	An interest rate swap matures.
February 11, 2026	Shares of common stock outstanding reported as 191,681,592.
February 13, 2026	Second Amendment to Receivables Facility, increasing credit availability from $80.0 million to $100.0 million and extending maturity date from October 31, 2026 to February 13, 2029.
February 16, 2026	Date of KPMG LLP's audit report.
February 17, 2026	Date of signing of the 10-K report.
March 13, 2026	Deadline for Borrower to deliver an amendment to the Purchase and Sale Agreement for additional Originators.
April 13, 2026	Deadline for Borrower to deliver an Account Control Agreement for the Collection Account at JPMorgan Chase Bank, N.A. and a related opinion of counsel.
April 30, 2026	Interest rate cap matures.
June 12, 2026	Deadline for Borrower or related Originator to instruct Obligors to remit payments for Pool Receivables to a Lock-Box and/or Collection Account at PNC Bank, National Association.
August 19, 2026	Expiration date of Matthew Hawkins' 10b5-1 trading plan.
March 31, 2027	Two interest rate swaps mature.
October 6, 2028	Revolving Credit Facility maturity date.
February 13, 2029	New maturity date for Receivables Facility (after Feb 13, 2026 amendment).
October 22, 2029	First Lien Credit Facility maturity date.
2030	Total addressable market projected to reach almost $25 billion.
2032	Federal Net Operating Losses (NOLs) begin to expire.
2033	National health expenditures expected to reach 20.3% of GDP.

Recommendation

buy

Waystar's strong financial performance in 2025, marked by a significant return to net profitability, robust revenue growth, and increased Adjusted EBITDA, indicates a positive trajectory. The strategic acquisition of Iodine Software and continued investment in AI-powered solutions position the company for sustained market leadership in the growing healthcare payments sector. High client retention and the ability to capitalize on market opportunities, such as the competitor's cybersecurity incident, demonstrate operational strength and competitive advantage. While substantial debt and the need for future capital raises are noted, the overall growth prospects, innovation, and strong market position make Waystar an attractive investment for long-term growth.

Keywords

Healthcare Payments, Revenue Cycle Management, AI Software, Waystar AltitudeAI, SEC Filing, 10-K, Financial Performance, Iodine Acquisition, Cloud-based Software, Healthcare Technology, Fintech, Corporate Governance, Risk Management, Nasdaq, WAY, Financial Reporting, Data Privacy, Cybersecurity, Debt Management, Investor Relations

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.